Janux Therapeutics (NASDAQ:JANX) Now Covered by Analysts at Jonestrading

Jonestrading assumed coverage on shares of Janux Therapeutics (NASDAQ:JANX) in a note issued to investors on Tuesday, Benzinga reports. The firm set a “buy” rating and a $70.00 price target on the stock. Jonestrading’s target price indicates a potential upside of 34.98% from the stock’s previous close.

Several other analysts also recently issued reports on the stock. BTIG Research assumed coverage on shares of Janux Therapeutics in a research note on Thursday, March 21st. They set a “buy” rating and a $62.00 target price on the stock. Bank of America boosted their price target on shares of Janux Therapeutics from $24.00 to $48.00 and gave the company a “buy” rating in a report on Wednesday, March 13th. William Blair restated an “outperform” rating on shares of Janux Therapeutics in a report on Tuesday, February 27th. Cantor Fitzgerald assumed coverage on shares of Janux Therapeutics in a report on Wednesday, March 20th. They set an “overweight” rating and a $100.00 price target on the stock. Finally, Wedbush restated an “outperform” rating and set a $53.00 price target on shares of Janux Therapeutics in a report on Monday, March 11th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, Janux Therapeutics currently has a consensus rating of “Buy” and an average price target of $61.33.

Janux Therapeutics Stock Performance

NASDAQ JANX opened at $51.86 on Tuesday. The business’s fifty day moving average is $32.00 and its two-hundred day moving average is $17.11. Janux Therapeutics has a 1 year low of $5.65 and a 1 year high of $58.69. The stock has a market capitalization of $2.68 billion, a P/E ratio of -38.70 and a beta of 4.19.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Friday, March 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.12. Janux Therapeutics had a negative net margin of 721.18% and a negative return on equity of 17.88%. The company had revenue of $2.46 million for the quarter, compared to the consensus estimate of $0.98 million. On average, research analysts forecast that Janux Therapeutics will post -1.41 earnings per share for the current year.

Institutional Investors Weigh In On Janux Therapeutics

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Janux Therapeutics by 3.9% during the fourth quarter. Vanguard Group Inc. now owns 979,483 shares of the company’s stock valued at $10,510,000 after buying an additional 37,202 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Janux Therapeutics by 174.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 39,948 shares of the company’s stock worth $429,000 after purchasing an additional 25,404 shares in the last quarter. Barclays PLC raised its position in Janux Therapeutics by 166.3% in the fourth quarter. Barclays PLC now owns 47,722 shares of the company’s stock worth $511,000 after purchasing an additional 29,800 shares in the last quarter. Nuveen Asset Management LLC raised its position in Janux Therapeutics by 22.3% in the fourth quarter. Nuveen Asset Management LLC now owns 81,574 shares of the company’s stock worth $875,000 after purchasing an additional 14,872 shares in the last quarter. Finally, Northern Trust Corp raised its position in Janux Therapeutics by 5.9% in the fourth quarter. Northern Trust Corp now owns 204,002 shares of the company’s stock worth $2,189,000 after purchasing an additional 11,317 shares in the last quarter. 75.39% of the stock is currently owned by institutional investors.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.